CD52 and B-cell chronic lymphocytic leukemia: Alemtuzumab represents a monoclonal antibody that targets CD52 and has demonstrated efficacy as a therapeutic option for chronic lymphocytic leukemia (CLL) and other lymphoid malignancies (35).